文献速递神经免疫

妊娠期多发性硬化复发甲泼尼龙治疗与子代神经发育的横断面研究

Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
PubMed 文献 · Neurology · 2025-10-16

本研究为两中心横断面研究,比较产前因母体多发性硬化复发接受甲泼尼龙治疗的足月儿(n=30)与未暴露参照组(n=30)。结果显示两组全局IQ无差异,次级神经心理学、脑电及MRI结构指标亦无组间差异;作者建议在更大随访研究前仍应谨慎使用最低有效剂量。

要点

  • 产前甲泼尼龙暴露组与参照组全局IQ无显著差异(103.0 vs 101.5)。
  • 次级神经心理学、脑电及脑结构MRI指标经多重比较校正后均无组间差异。
  • 多数暴露发生于孕中期,中位累积剂量5 g;仍需谨慎使用最低有效剂量。

核心结论

  • 本队列未发现产前甲泼尼龙暴露对学龄期子代神经发育的显著不良影响,但研究把握度不足以排除细微关联或剂量反应关系。

研究设计与样本

  • 横断面、两中心研究,比较产前因母体多发性硬化复发接受甲泼尼龙治疗的足月儿(n=30)与未暴露参照组(n=30),主要经德国多发性硬化与妊娠登记处识别。

主要发现

  • 甲泼尼龙暴露组与参照组全局IQ分别为103.0(95%CI 99.2-106.8)与101.5(95%CI 97.6-105.3),无显著差异。
  • 经多重比较校正后,次级神经心理学结局及脑电参数均无组间差异。
  • MRI分析显示灰质体积、皮层厚度、脑回化及脑龄均无组间差异。

关键数值与推荐

  • 甲泼尼龙暴露组中位累积剂量为5 g(Q1-Q3:3-7.5),主要于孕中期给药。
  • 暴露组平均年龄9.6岁、女性37%;参照组平均年龄10.0岁、女性40%。

临床怎么用

  • 对于妊娠期多发性硬化复发,甲泼尼龙治疗未显示子代神经发育损害,但仍建议以最低有效剂量谨慎使用。

局限性

  • 研究把握度不足以检测次级分析中的细微关联,也无法对潜在剂量反应关系作出 definitive 结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: High-dose methylprednisolone (MP) is the global standard for treating pregnancy-associated relapses in multiple sclerosis (MS). Given that glucocorticoids cross the placenta and may interfere with fetal brain development, concerns remain about their long-term safety. This study assessed whether in utero MP exposure as part of MS relapse therapy affects neurodevelopment in school-aged children. METHODS: In this cross-sectional, 2-center study, term-born children with prenatal exposure to MP due to maternal MS relapse treatment were compared with a nonexposed reference group of children, all born to mothers with MS. Participants were primarily identified using the German MS and Pregnancy Registry and assessed at tertiary MS centers. The primary outcome was global cognitive ability, measured using a standardized intelligence test. Secondary outcomes included attention, behavior, motor performance, and electrocortical activity at rest. Structural brain development was assessed using high-resolution MRI, including voxel-based and surface-based morphometry. Deviations from chronological brain age were quantified using a machine learning-based framework. Statistical associations were examined using linear regression models. RESULTS: The MP-exposed group (n = 30; mean age 9.6 years; 37% female) and the reference group (n = 30; mean age 10.0 years; 40% female) were comparable with respect to demographic and perinatal characteristics. The median cumulative MP dose was 5 g (Q1-Q3: 3-7.5), predominantly administered during the second trimester. Global IQ did not differ between groups (MP: 103.0; 95% CI: 99.2-106.8 vs reference: 101.5; 95% CI: 97.6-105.3). After correction for multiple comparisons, no group differences emerged in secondary neuropsychological outcomes or electrocortical parameters. MRI analyses revealed no differences in gray matter volume, cortical thickness, gyrification, or chronological brain age. DISCUSSION: In spite of theoretical concerns that MP exposure during pregnancy might lead to alterations in neurodevelopment, this was not found to be the case in this cohort, with most exposures occurring during the second trimester. However, this study was not powered to detect subtle associations in secondary analyses or to draw definitive conclusions regarding potential dose-response relationships. Given the remaining uncertainties, MP should be used with caution at the lowest effective dose until larger follow-up studies provide further clarity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kozik V, Dreiling M, Müller D, et al. Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study. Neurology. 2025. PMID: 41100780. doi:10.1212/WNL.0000000000214217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。